Molecular pathology selected abstracts
April 2026—Use of long-read sequencing to monitor diagnostic blind spots of inherited metabolic diseases; Diffuse large B-cell lymphoma: a biologically heterogenous disease
Webinars and Sponsored Roundtables — Register Now
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Columns
Pathology informatics selected abstracts
April 2026—Technical considerations during validation of Genius digital diagnostic system; Applicability of accreditation requirements to machine learning-based methods in molecular oncology testing
Q&A column
April 2026
Q. Do regulatory agencies still support sodium citrate platelet counts? What is the CAP’s standing? Read answer.
Newsbytes
April 2026—PathGroup, a clinical laboratory, partnered with Labgnostic to automate proficiency testing order entry and result delivery. LabgnosticPT, an application from Labgnostic, automates the PT process, integrating with laboratory information systems for seamless order and result transmission. This automation significantly reduces administrative time, allowing PathGroup staff to focus more on patient-centered work.
Put It on the Board
April 2026—Vitestro raised $70 million in Series B financing to advance its Aletta robotic phlebotomy device. The funding will support product development, manufacturing, clinical expansion, and commercial readiness for the Aletta, which uses imaging, robotics, and AI for blood collection.
From the President’s Desk
March 2026—International medical graduates are crucial to the American healthcare system, particularly in pathology, where they make up a significant portion of the workforce.
Clinical pathology selected abstracts
March 2026—Continuous glucose monitoring is recommended for type 1 and type 2 diabetes patients, particularly those using insulin.
Anatomic pathology selected abstracts
March 2026—A study developed an AI-based system, ATLS-8, to quantify CD8+ tumor-infiltrating lymphocytes and assess their prognostic value in hepatocellular carcinoma patients undergoing liver resection.
Molecular pathology selected abstracts
March 2026—A study at UPHS and MGB found racial and socioeconomic disparities in access to genetic evaluation.
Newsbytes
March 2026—Pathologist Scott Robertson, MD, PhD, developed PIRO, a web-based search platform that converts narrative information in pathology reports into searchable concepts.